

Notice of Allowability

Application No.

10/506,554

Applicant(s)

WHITTAMORE ET AL.

Examiner

Art Unit

Jason M. Nolan, Ph.D.

1626

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to 3/1/2004.
2. ☒ The allowed claim(s) is/are 1-14.
3. ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some* c) ☐ None of the:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☒ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

4. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
- (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
- 1) ☐ hereto or 2) ☐ to Paper No./Mail Date _____.
- (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.
- Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☒ Notice of References Cited (PTO-892)
2. ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. ☒ Information Disclosure Statements (PTO-1449 or PTO/SB/08), Paper No./Mail Date 3/24/2005
4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material
5. ☐ Notice of Informal Patent Application (PTO-152)
6. ☐ Interview Summary (PTO-413), Paper No./Mail Date _____.
7. ☐ Examiner's Amendment/Comment
8. ☒ Examiner's Statement of Reasons for Allowance
9. ☐ Other _____.

DETAILED ACTION

Claims 1-14 are currently pending in the instant application.

Priority

This application is a 371 of PCT/GB03/00883, filed on March 3, 2003.


Acknowledgement is made of Applicant's claim for foreign priority via United Kingdom 0205176.1, filed on March 6, 2002.

Information Disclosure Statement

Applicant's information disclosure statement (IDS), filed on March 24, 2005 has been considered. Please refer to Applicant's copies of the 1449 submitted herewith.

Reasons for Allowance

The present invention relates to compounds of formula 1 in **Claim 1** (shown below), which contain an indole core substituted at C-2 with a fused bicyclic ring system consisting of a saturated ring and ring **A**, connected to the indole via an amide bond. The bicyclic ring system contains the substituent **Y**, which is either NR^2R^3 or OR^3 . The combination of these substitutions, and more explicitly the saturated ring moiety, affords novelty to this invention and no prior art anticipates or renders this invention obvious.




This invention also includes pharmaceutical compositions of formula 1 for the treatment of type 2 diabetes, insulin resistance, syndrome X, hyperinsulinaemia,

Art Unit: 1626

hyperglucagonaemia, cardiac ischaemia, or obesity as well as their methods for preparation.

The closest prior art are the compounds disclosed by Lee in US Patent 6660742, for which the bicyclic ring system is a substituted naphthalene ring, and therefore does not read on the claims of the instant application.



core of the compounds in US Patent 6660742

Telephone Inquiry

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to **Jason M. Nolan, Ph.D.** whose telephone number is **(571) 272-4356**. The Examiner can normally be reached on Monday - Friday (9:00 - 5:30PM).

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Joseph McKane can be reached on (571) 272-0699. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Art Unit: 1626

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



Jason M. Nolan, Ph.D.
Patent Examiner
Art Unit 1626



Joseph McKane
Supervisory Patent Examiner
Art Unit 1626
Date: March 25, 2006